Bleichroeder LP Reports New 6.86% Stake in Ernexa Therapeutics Inc.

On May 14, 2026, Bleichroeder LP, along with Bleichroeder Holdings LLC and Andrew Gundlach, filed a Schedule 13G regarding their holdings in Ernexa Therapeutics Inc. (ERNA). The filing reveals that as of March 31, 2026, the reporting persons beneficially own 80,000 shares of common stock, representing a 6.86% ownership stake. This position is a significant increase from the previously reported 0.0% ownership. The filing notes that Bleichroeder LP also holds warrants that are subject to a 4.99% exercise limitation. If this limitation were not in place, the reporting persons would be deemed to beneficially own a total of 160,000 shares (including 80,000 shares issuable upon warrant exercise), which would represent approximately 12.84% of the issuer's outstanding common stock. The securities were acquired in the ordinary course of business and are not held for the purpose of influencing or changing the control of the issuer. Andrew Gundlach serves as the President and CEO of both Bleichroeder LP and Bleichroeder Holdings LLC.